» Articles » PMID: 34572889

MiR-137 Targets the 3' Untranslated Region of : Potential Implications in Lynch Syndrome-Related Colorectal Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Sep 28
PMID 34572889
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Mismatch Repair () gene dysregulation plays a fundamental role in Lynch Syndrome (LS) pathogenesis, a form of hereditary colorectal cancer. Loss or overexpression of key genes leads to genome instability and tumorigenesis; however, the mechanisms controlling gene expression are unknown. One such gene, , exerts an important role, not only in MMR, but also in cell proliferation, apoptosis, and cell cycle control. In this study, we explored the functions and underlying molecular mechanisms of increased expression related to a c.*226A>G variant in the 3'untranslated (UTR) region of that had been previously identified in a subject clinically suspected of LS. Bioinformatics identified a putative binding site for miR-137 in this region. To verify miRNA targeting specificity, we performed luciferase gene reporter assays using a 3'UTR psiCHECK-2 vector in human SW480 cells over-expressing miR-137, which showed a drastic reduction in luciferase activity ( > 0.0001). This effect was abolished by site-directed mutagenesis of the putative miR-137 seed site. Moreover, in these cells we observed that miR-137 levels were inversely correlated with expression levels. These results were confirmed by results in normal and tumoral tissues from the patient carrying the 3'UTR c.*226A>G variant in Finally, miR-137 overexpression in SW480 cells significantly suppressed cell proliferation in a time- and dose-dependent manner ( < 0.0001), supporting a role for MSH2 in apoptosis and cell proliferation processes. Our findings suggest miR-137 helps control expression via its 3'UTR and that dysregulation of this mechanism appears to promote tumorigenesis in colon cells.

Citing Articles

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice.

Ascrizzi S, Arillotta G, Grillone K, Carida G, Signorelli S, Ali A Cancers (Basel). 2023; 15(15).

PMID: 37568746 PMC: 10417124. DOI: 10.3390/cancers15153930.


Hereditary Colorectal Cancer: State of the Art in Lynch Syndrome.

Nolano A, Medugno A, Trombetti S, Liccardo R, De Rosa M, Izzo P Cancers (Basel). 2023; 15(1).

PMID: 36612072 PMC: 9817772. DOI: 10.3390/cancers15010075.


Systemic circulating microRNA landscape in Lynch syndrome.

Sievanen T, Korhonen T, Jokela T, Ahtiainen M, Lahtinen L, Kuopio T Int J Cancer. 2022; 152(5):932-944.

PMID: 36282188 PMC: 10092425. DOI: 10.1002/ijc.34338.

References
1.
Banno K, Yanokura M, Iida M, Masuda K, Aoki D . Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics. J Obstet Gynaecol Res. 2014; 40(8):1957-67. DOI: 10.1111/jog.12442. View

2.
Coppede F . The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2014; 8(8):935-48. DOI: 10.1586/17474124.2014.924397. View

3.
Landau D, Slack F . MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin Oncol. 2011; 38(6):743-51. PMC: 3217196. DOI: 10.1053/j.seminoncol.2011.08.003. View

4.
Smrt R, Szulwach K, Pfeiffer R, Li X, Guo W, Pathania M . MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells. 2010; 28(6):1060-70. PMC: 3140955. DOI: 10.1002/stem.431. View

5.
Cummins J, He Y, Leary R, Pagliarini R, Diaz Jr L, Sjoblom T . The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006; 103(10):3687-92. PMC: 1450142. DOI: 10.1073/pnas.0511155103. View